CoChat

Topiramate in the treatment of obese subjects with drug‐naive type 2 diabetes

Stenlöf, K., Rössner, S., Vercruysse, F., Kumar, A., Fitchet, M., Sjöström, L., Study Group · 2007 · Diabetes, Obesity and Metabolism
Cited by 77

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aim: The aim of this study was to examine the efficacy and safety of topiramate as an adjunct to diet and exercise in drug‐naive, obese subjects with type 2 diabetes. Methods: Drug‐naive individuals with type 2 diabetes, body mass index (BMI) of ≥27 and <50 kg/m 2 and haemoglobin A 1c (HbA 1c ) of <10.5% were enrolled into the study. All the individuals participated in a non‐pharmacologic weight loss program (Pathways to Change ® ; Johnson & Johnson Healthcare Systems, Piscataway, NJ, USA) throughout the trial. After a 6‐week placebo run‐in, the subjects were randomized to placebo, topiramate 96 mg/day or topiramate 192 mg/day. Subjects were scheduled for 8‐week titration and 52‐week maintenance phases. The study was ended early; efficacy data were reported for a predefined modified intent‐to‐treat (MITT) population (n = 229), with 40 weeks of treatment. All the subjects who provided any safety data were included in the safety population (n = 535). Results: Baseline mean weight was 103.7 kg, BMI 36 kg/m 2 and HbA 1c 6.7% across all treatment groups. By the end of week 40, the placebo, the topiramate 96 mg/day and topiramate 192 mg/day groups lost 2.5, 6.6 and 9.1% of their baseline body weight respectively (p < 0.001 vs. placebo, MITT population using last observation carried forward). The decrease in HbA 1c was 0.2, 0.6 and 0.7% respectively (p < 0.001 vs. placebo, MITT). Topiramate significantly reduced blood pressure and urinary albumin excretion; a weight‐loss‐independent HbA 1c improving effect of topiramate was demonstrated. Adverse events were predominantly related to central nervous system (CNS). Conclusions: Topiramate as an add‐on treatment to lifestyle improvements produced significant weight loss and improved glucose homeostasis in obese, drug‐naive subjects with type 2 diabetes. These treatment advantages should be balanced against the occurrence of adverse events in the CNS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2006.00618.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 77

Metadata

Authors
Stenlöf, K., Rössner, S., Vercruysse, F., Kumar, A., Fitchet, M., Sjöström, L., & Study Group
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2006-08-04
Volume
9
Issue
3
Pages
360-368
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1967462033
Cited by
77
References
12
FWCI
3.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Topiramate in the treatment of obese subjects with drug‐naive type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2006.00618.x
The paper
Stenlöf, K., Rössner, S., Vercruysse, F., Kumar, A., Fitchet, M., Sjöström, L., & Study Group. (2007). Topiramate in the treatment of obese subjects with drug‐naive type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2006.00618.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.